MCID: ADN021
MIFTS: 76

Adenomatous Polyposis Coli malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Gastrointestinal diseases, Skin diseases, Fetal diseases, Bone diseases

Aliases & Classifications for Adenomatous Polyposis Coli

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 27GTR, 31ICD10 via Orphanet, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot, 71Wikipedia
See all MalaCards sources

Aliases & Descriptions for Adenomatous Polyposis Coli:

Name: Adenomatous Polyposis Coli 52 48 24 25 12 39 68
Familial Adenomatous Polyposis 11 71 48 24 25 54 70 50 13
Gardner Syndrome 52 48 24 54 68
Fap 48 24 25 54 70
Brain Tumor-Polyposis Syndrome 2 52 27 68
Familial Multiple Polyposis Syndrome 25 27
Adenomatous Polyposis of the Colon 11 48
Familial Adenomatous Polyposis 1 52 27
Familial Intestinal Polyposis 48 68
Familial Polyposis Coli 24 54
Gardner's Syndrome 48 27
Polyposis Coli and Multiple Hard and Soft Tissue Tumors 48
Apc-Related Attenuated Familial Adenomatous Polyposis 54
Intestinal Polyposis, Osteomas, Sebaceous Cysts 48
Apc-Related Attenuated Familial Polyposis Coli 54
 
Familial Adenomatous Polyposis of the Colon 48
Adenomatous Familial Polyposis Syndrome 25
Polyposis, Adenomatous Intestinal 48
Colorectal Adenomatous Polyposis 54
Familial Polyposis of the Colon 48
Turcot Syndrome with Polyposis 54
Adenomatous Familial Polyposis 25
Familial Multiple Polyposis 48
Apc-Related Attenuated Fap 54
Hereditary Polyposis Coli 48
Mutyh-Associate Polyposis 68
Myh-Associated Polyposis 25
Gardners Syndrome 50
Apc-Related Afap 54
Fpc 48

Characteristics:

Orphanet epidemiological data:

54
familial adenomatous polyposis:
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-9/100000 (Europe),1-5/10000 (Denmark),1-9/100000 (Denmark),1-9/100000 (Sweden),1-5/10000 (Finland),1-9/100000 (Finland),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/1000000 (Australia),1-9/100000 (Australia); Age of onset: Adult; Age of death: adult
apc-related attenuated familial adenomatous polyposis:
Inheritance: Autosomal dominant,Autosomal recessive
turcot syndrome with polyposis:
Inheritance: Autosomal dominant; Age of onset: All ages

HPO:

64
adenomatous polyposis coli:
Inheritance: autosomal dominant inheritance
Onset and clinical course: variable expressivity

Classifications:



External Ids:

OMIM52 175100
Disease Ontology11 DOID:0050424
MeSH39 D011125
NCIt45 C3339
MESH via Orphanet40 D011125, D005736
ICD10 via Orphanet31 D12.6
UMLS via Orphanet69 C0032580, C0017097
UMLS68 C0032580, C2713442, C2713443

Summaries for Adenomatous Polyposis Coli

About this section
NIH Rare Diseases:48 Familial adenomatous polyposis (FAP) is an inherited condition that causes cancer of the large intestine (colon) and rectum. People with the classic type of FAP usually develop hundreds to thousands of noncancerous (benign) polyps (growths) in the colon as early as their teenage years. Overtime, these polyps can become malignant (cancerous), leading to early-onset colorectal cancer at an average age of 39 years. Other signs and symptoms may include dental abnormalities; desmoid tumors; and benign and malignant tumors of the duodenum (a section of the small intestine), stomach, bones, skin, and other tissues. Some people have a milder form of the condition called attenuated familial adenomatous polyposis (AFAP) which is generally characterized by fewer colon polyps (an average of 30) and a delay in the development of colon cancer by 10-15 years. FAP is caused by changes (mutations) in the APC gene and is inherited in an autosomal dominant manner. People with FAP usually undergo regular screening until they develop 20 to 30 polyps and then a colectomy (removal of colon) is generally recommended. Last updated: 11/26/2014

MalaCards based summary: Adenomatous Polyposis Coli, also known as familial adenomatous polyposis, is related to mismatch repair cancer syndrome and gastric cancer, and has symptoms including adenomatous colonic polyposis, intestinal polyposis and duodenal polyposis. An important gene associated with Adenomatous Polyposis Coli is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways are RHO GTPases activate IQGAPs and N-cadherin signaling events. The drug celecoxib has been mentioned in the context of this disorder. Affiliated tissues include colon, skin and thyroid, and related mouse phenotypes are Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation and limbs/digits/tail.

Disease Ontology:11 An autosomal dominant disease that is has material basis in mutations in the APC gene and involves formation of numerous polyps in the epithelium of the large intestine which are initially benign and later transform into colon cancer.

Genetics Home Reference:25 Familial adenomatous polyposis (FAP) is an inherited disorder characterized by cancer of the large intestine (colon) and rectum. People with the classic type of familial adenomatous polyposis may begin to develop multiple noncancerous (benign) growths (polyps) in the colon as early as their teenage years. Unless the colon is removed, these polyps will become malignant (cancerous). The average age at which an individual develops colon cancer in classic familial adenomatous polyposis is 39 years. Some people have a variant of the disorder, called attenuated familial adenomatous polyposis, in which polyp growth is delayed. The average age of colorectal cancer onset for attenuated familial adenomatous polyposis is 55 years.

OMIM:52 Familial adenomatous polyposis-1 is an autosomal dominant disorder characterized by predisposition to cancer. Affected... (175100) more...

UniProtKB/Swiss-Prot:70 Familial adenomatous polyposis: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.

Wikipedia:71 This article refers to the tumor suppressor APC, in which mutations lead to colon cancer. For the... more...

Related Diseases for Adenomatous Polyposis Coli

About this section

Diseases related to Adenomatous Polyposis Coli via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 160)
idRelated DiseaseScoreTop Affiliating Genes
1mismatch repair cancer syndrome31.6APC, CTNNB1, MLH1, MSH2, PMS1
2gastric cancer30.3CCND1, MYC, TP53
3medulloblastoma30.2APC, AXIN1, CTNNB1, MYC, TP53
4oral lichen planus30.0CCND1, CDH1, PTGS2, TP53
5desmoid disease, hereditary29.5AMER1, APC, APC2, AXIN1, AXIN2, CCND1
6lung cancer29.0AXIN2, CCND1, CDH1, CTNNB1, MLH1, MYC
7hepatocellular carcinoma29.0APC, AXIN1, CCND1, CDH1, CTNNB1, MSH2
8breast cancer28.9APC, CCND1, CDH1, CTNNB1, MLH1, MSH2
9colorectal cancer27.1APC, AXIN1, AXIN2, CCND1, CDH1, CTNNB1
10samson gardner syndrome11.8
11amyloidosis, hereditary, transthyretin-related11.6
12attenuated familial adenomatous polyposis11.5
13mutyh-associated polyposis11.2
14ehlers-danlos syndrome, type viic10.8APC, CTNNB1
15colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas10.8
16duodenum cancer10.8
17oral tuberculosis10.7CDH1, TP53
18gastric cancer, somatic10.6APC, CDH1, MUTYH
19emerinopathy10.6AXIN1, CTNNB1, TP53
20malignant hyperthermia susceptibility10.6APC, MUTYH, TP53
21herpes simplex encephalitic 610.6APC, CTNNB1, TP53
22extrahepatic bile duct adenocarcinoma10.6CDH1, CTNNB1, TP53
23stromal keratitis10.6CDH1, CTNNB1, TP53
24hemochromatosis type 210.6CCND1, CTNNB1, MYC
25ampulla of vater squamous cell carcinoma10.5APC, MLH1, TP53
26foramen magnum meningioma10.5CTNNB1, MYC, TP53
27childhood type dermatomyositis10.5CDH1, CTNNB1, TP53
28pancreatic somatostatinoma10.5CDH1, CTNNB1, TP53
29myelophthisic anemia10.5APC, CTNNB1, PTGS2
30renal pelvis inverted papilloma10.5CDH1, TP53
31ductal carcinoma in situ10.5CCND1, CDH1, TP53
32integumentary system cancer10.5CCND1, CDH1, TP53
33nodular degeneration of cornea10.4CTNNB1, MLH1, TP53
34clear cell acanthoma10.4MLH1, MYC, TP53
35bilateral retinoblastoma10.4CCND1, MYC, TP53
36mature b-cell neoplasm10.4AXIN1, AXIN2, CTNNB1, TP53
37pharynx cancer10.4CCND1, MYC, TP53
38infiltrating lipoma10.4PTGS2, TP53
39richter's syndrome10.4CCND1, CDH1, TP53
40ascending colon cancer10.4CCND1, MYC, TP53
41adenoma10.4
42acquired amegakaryocytic thrombocytopenia10.4APC, MSH2, MUTYH
43chondroma10.4CCND1, CDH1, TP53
44stenosis of lacrimal sac10.4CCND1, MYC, TP53
45urinary tract obstruction10.4CTNNB1, PTGS2, TP53
46large intestine adenocarcinoma10.4MLH1, MSH2
47hodgkin's granuloma10.4CCND1, CDH1, CTNNB1, TP53
48pituitary carcinoma10.4MYC, PTGS2, TP53
49lobular neoplasia10.4CCND1, CDH1, CTNNB1, TP53
50nasal cavity adenocarcinoma10.4CCND1, CDH1, CTNNB1, TP53

Graphical network of the top 20 diseases related to Adenomatous Polyposis Coli:



Diseases related to adenomatous polyposis coli

Symptoms & Phenotypes for Adenomatous Polyposis Coli

About this section

Symptoms by clinical synopsis from OMIM:

175100

Clinical features from OMIM:

175100

Human phenotypes related to Adenomatous Polyposis Coli:

 64 54 (show all 34)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 adenomatous colonic polyposis64 54 hallmark (90%) Very frequent (99-80%) HP:0005227
2 intestinal polyposis64 hallmark (90%) HP:0200008
3 duodenal polyposis64 54 typical (50%) Very frequent (99-80%) HP:0004783
4 neoplasm of the colon64 typical (50%) HP:0100273
5 colon cancer64 54 frequent (33%) Frequent (79-30%) HP:0003003
6 multiple gastric polyps64 54 frequent (33%) Very frequent (99-80%) HP:0004394
7 adrenocortical adenoma64 13% HP:0008256
8 desmoid tumors64 10% HP:0100245
9 carious teeth64 occasional (7.5%) HP:0000670
10 delayed eruption of teeth64 54 occasional (7.5%) Occasional (29-5%) HP:0000684
11 unerupted tooth64 occasional (7.5%) HP:0000706
12 multiple lipomas64 54 occasional (7.5%) Occasional (29-5%) HP:0001012
13 neoplasm of the nervous system64 occasional (7.5%) HP:0004375
14 irregular hyperpigmentation64 54 occasional (7.5%) Occasional (29-5%) HP:0007400
15 congenital hypertrophy of retinal pigment epithelium64 occasional (7.5%) HP:0007649
16 fibroadenoma of the breast64 occasional (7.5%) HP:0010619
17 increased number of teeth64 54 occasional (7.5%) Occasional (29-5%) HP:0011069
18 sarcoma64 54 occasional (7.5%) Occasional (29-5%) HP:0100242
19 osteoma64 occasional (7.5%) HP:0100246
20 odontogenic neoplasm64 occasional (7.5%) HP:0100612
21 epidermoid cyst64 occasional (7.5%) HP:0200040
22 duodenal adenocarcinoma64 4% HP:0006771
23 hepatoblastoma64 1.6% HP:0002884
24 medulloblastoma64 very rare (1%) HP:0002885
25 papillary thyroid carcinoma64 very rare (1%) HP:0002895
26 hyperpigmentation of the skin64 HP:0000953
27 small intestine carcinoid64 HP:0006722
28 adrenocortical carcinoma64 HP:0006744
29 astrocytoma64 HP:0009592
30 keloids64 HP:0010562
31 odontoma64 54 Occasional (29-5%) HP:0011068
32 neoplasm54 Frequent (79-30%)
33 fibroma54 Occasional (29-5%)
34 neoplasm of the central nervous system54 Occasional (29-5%)

UMLS symptoms related to Adenomatous Polyposis Coli:


diarrhea, abdominal pain

GenomeRNAi Phenotypes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00016-A9.6APC, AXIN1, AXIN2, GSK3B, MCC, MSH2

MGI Mouse Phenotypes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

41 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053719.3AMER1, APC, AXIN1, AXIN2, CTNNB1, MYC
2MP:00030129.1APC, AXIN2, CDH1, CTNNB1, GSK3B, MYC
3MP:00053808.9AMER1, APC, AXIN1, AXIN2, CDH1, CTNNB1
4MP:00053678.9AMER1, APC, AXIN1, CTNNB1, GSK3B, PTGS2
5MP:00107718.8APC, CCND1, CDH1, CTNNB1, MLH1, MSH2
6MP:00053798.7APC, AXIN2, CCND1, CDH1, CTNNB1, GSK3B
7MP:00053898.6APC, APC2, AXIN1, AXIN2, CCND1, CDH1
8MP:00053828.6AMER1, APC, AXIN1, AXIN2, CCND1, CTNNB1
9MP:00020068.5APC, CCND1, CDH1, CTNNB1, MLH1, MSH2
10MP:00053908.5AMER1, APC, AXIN1, AXIN2, CCND1, CTNNB1
11MP:00053878.3AMER1, APC, CCND1, CDH1, CTNNB1, GSK3B
12MP:00028738.2APC, AXIN1, AXIN2, CCND1, CDH1, CTNNB1
13MP:00036318.0APC, APC2, AXIN1, AXIN2, CCND1, CTNNB1
14MP:00053787.9AMER1, APC, APC2, AXIN1, AXIN2, CCND1
15MP:00053857.8AMER1, APC, AXIN1, AXIN2, CCND1, CDH1
16MP:00053847.8AMER1, APC, APC2, AXIN1, AXIN2, CCND1
17MP:00053817.7APC, AXIN1, CCND1, CDH1, CTNNB1, GSK3B
18MP:00053767.7AMER1, APC, CCND1, CDH1, CTNNB1, GSK3B
19MP:00107687.5AMER1, APC, AXIN1, AXIN2, CCND1, CDH1

Drugs & Therapeutics for Adenomatous Polyposis Coli

About this section

Drugs for Adenomatous Polyposis Coli (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 76)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Erythromycinapproved, vet_approvedPhase 495114-07-812560
Synonyms:
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione
,10-dione
114-07-8
3''-O-demethylerythromycin
374700-25-1
45673_FLUKA
45674_FLUKA
79235-06-6
82343-12-2
A/T/S
AC-12744
AC1L1FIQ
AC1L1QK7
AC1L1ZUR
AC1O8PVA
AC1Q2UA1
AC1Q6O1S
AI3-50138
AR-1A4414
AR-1H0723
Abboticin
Abomacetin
Acneryne
Acnesol
Ak-Mycin
Ak-mycin
Akne Cordes Losung
Akne-Mycin
Akne-mycin (TN)
Aknederm Ery Gel
Aknemycin
Aknin
AustriaS
BB_NC-1332
BIDD:GT0017
BPBio1_000312
BSPBio_000282
BSPBio_002480
Benzamycin
Benzamycin Pak
Bristamycin
C-Solve-2
C01912
C37H67NO13
CCRIS 9078
CHEBI:42355
CHEMBL532
CID12560
CID3255
CID6713919
CID8233
D00140
DB00199
Del-Mycin
Derimer
Deripil
DivK1c_000294
DivK1c_000397
DivK1c_000702
Dotycin
Dumotrycin
E- mycin, Erycin, Robimysin
E-Base
E-Base (base)
E-Glades
E-Mycin
E-Mycin (base)
E-Solve 2
E0751
E0774_SIAL
E5389_SIGMA
E6376_SIAL
E7904_SIGMA
EINECS 204-040-1
EM
EMU
ERY
ERYC
ERYC (base)
ERYTHROMYCIN STEARATE
ETS
Emgel
Emu-V
Emu-Ve
Emuvin
Emycin
Endoeritrin
Erecin
Erimycin-T
Erisone
Eritomicina
Eritrocina
Eritromicina
Eritromicina [INN-Spanish]
Ermycin
Eros
Ery-B
Ery-Diolan
Ery-Sol
Ery-Tab
Ery-Tab (base)
Ery-maxin
Eryacne
Eryacnen
Eryc
Eryc (TN)
Eryc 125
Eryc Sprinkles
Eryc-125
Eryc-250
Erycen
Erycette
Erycin
Erycinum
Eryderm
Erydermer
Erygel
Erygel (TN)
Eryhexal
Erymax
Erymed
Erypar
Erysafe
Erytab
Erythra-Derm
Erythro
Erythro-Statin
Erythro-Teva
Erythrocin
Erythrocin Stearate
Erythroderm
Erythrogran
Erythroguent
Erythromast 36
Erythromid
Erythromycin
Erythromycin & VRC3375
Erythromycin (JP15/USP/INN)
 
Erythromycin A
Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279
Erythromycin B
Erythromycin C
Erythromycin Lactate
Erythromycin Ointment
Erythromycin Stearate
Erythromycin [INN:BAN:JAN]
Erythromycin base
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin glucoheptonate
Erythromycin intravenous
Erythromycin lactobionate
Erythromycin oxime
Erythromycin sodium lauryl sulfate
Erythromycin, compd. with monododecyl sulfate, sodium salt
Erythromycine
Erythromycine [INN-French]
Erythromycinum
Erythromycinum [INN-Latin]
Erytop
Erytrociclin
Ethril 250
HMS1568O04
HMS1920M04
HMS2091D05
HMS500O16
HSDB 3074
I06-0245
IDI1_000294
IDI1_000397
IDI1_000702
Ilocaps
Ilosone
Ilosone (estolate)
Iloticina
Ilotycin
Ilotycin Gluceptate
Ilotycin T.S
Ilotycin T.S.
Inderm
Inderm Gel
IndermRetcin
KBio1_000294
KBio1_000397
KBio1_000702
KBio2_000555
KBio2_001139
KBio2_003123
KBio2_003707
KBio2_005691
KBio2_006275
KBioGR_001175
KBioSS_000555
KBioSS_001139
KST-1A8261
Kesso-Mycin
LMPK04000006
LS-187077
LS-64648
Latotryd
Lederpax
MLS001066618
Mephamycin
Mercina
MolPort-000-772-161
MolPort-002-507-378
MolPort-003-933-429
N-Methylerythromycin A
NCGC00179619-01
NCI-C55674
NINDS_000294
NINDS_000397
NINDS_000702
NSC 55929
NSC55929
Oftalmolosa Cusi Eritromicina
Oftamolets
PCE Dispertab (base)
Paediathrocin
Pantoderm
Pantodrin
Pantomicina
Pce
Pce (TN)
Pfizer-e
Pharyngocin
Prestwick0_000151
Prestwick1_000151
Prestwick2_000151
Prestwick3_000151
Prestwick_205
Primacine
Propiocine
Proterytrin
R-P Mycin
Retcin
Robimycin
Romycin
SBB057401
SMP1_000119
SMR000544946
SPBio_000778
SPBio_001226
SPBio_002221
SPECTRUM1500280
STK249736
Sans-acne
Sansac
Serp-AFD
Skid Gel E
Spectrum2_000759
Spectrum2_001263
Spectrum4_000538
Spectrum5_001596
Spectrum_000115
Spectrum_000659
Staticin
Staticin (TN)
Stiemicyn
Stiemycin
Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin
T-Stat
T-stat (TN)
Taimoxin-F
Theramycin Z
Tiloryth
Tiprocin
Torlamicina
UNII-63937KV33D
Udima Ery Gel
Wemid
Wyamycin S
adecane-2,10-dione (non-preferred name)
bmse000664
erythro
erythromycin
nchembio.285-comp13
érythromycine
2
Celecoxibapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1435169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
3Antirheumatic AgentsPhase 4, Phase 2, Phase 3, Phase 110627
4Cyclooxygenase 2 InhibitorsPhase 4, Phase 2, Phase 3, Phase 1616
5Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 2, Phase 3, Phase 14295
6Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 122776
7Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 110355
8Cyclooxygenase InhibitorsPhase 4, Phase 2, Phase 3, Phase 12778
9Analgesics, Non-NarcoticPhase 4, Phase 2, Phase 3, Phase 16260
10Erythromycin EstolatePhase 495
11Anti-Infective AgentsPhase 4, Phase 3, Phase 1, Phase 221402
12Erythromycin EthylsuccinatePhase 495
13Erythromycin stearatePhase 495
14AnalgesicsPhase 4, Phase 2, Phase 3, Phase 111287
15Gastrointestinal AgentsPhase 4, Phase 2, Phase 38109
16Anti-Bacterial AgentsPhase 4, Phase 1, Phase 210884
17
SulindacapprovedPhase 3, Phase 23738194-50-25352, 1548887
Synonyms:
(E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((P-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid
(Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid
32004-68-5
38194-50-2
5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid
53933-60-1
6301-55-9
9000-14-0
AB00513800
AC-4550
AC1L1K5T
AC1LU7GU
AC1LU7GY
AC1Q6YHK
AKOS004119989
AR-1A9609
Aclin
Aflodac
Alphapharm Brand of Sulindac
Apo Sulin
Apo-Sulin
Apotex Brand of Sulindac
Arthrobid
Arthrocine
BB_SC-1128
BPBio1_000315
BRD-A03427350-001-01-3
BRD-A13946108-001-04-9
BRN 2951842
BSPBio_000285
BSPBio_002890
C01531
C20H17FO3S
CAS-38194-50-2
CCRIS 3305
CHEBI:9352
CHEMBL1376
CID1548885
CID1548887
CID5352
CPD000326718
Cahill May Roberts Brand of Sulindac
Chemia Brand of Sulindac
Chibret
Clinoril
Clinoril (TN)
Copal
Copal resin
Copal rosin varnish
Copals
D00120
D013467
DB00605
DivK1c_000601
EINECS 232-527-9
EINECS 250-893-8
EINECS 253-819-2
EINECS 258-873-0
EU-0101070
Gum copal
HMS1568O07
HMS1921C11
HMS2089J04
HMS2092K15
HMS501O03
I06-0523
IDI1_000601
KBio1_000601
KBio2_001506
KBio2_002320
KBio2_004074
KBio2_004888
KBio2_006642
KBio2_007456
KBio3_002110
KBio3_002800
KBioGR_001571
 
KBioGR_002320
KBioSS_001506
KBioSS_002322
KST-1B6530
Kenalin
Kendrick Brand of Sulindac
Klinoril
LS-81610
Lopac-S-8139
Lopac0_001070
MK 231
MK-231
MK231
MLS001056554
MLS001304027
MLS002207124
Merck Brand of Sulindac
Merck Sharp & Dohme Brand of Sulindac
Mobilin
MolPort-002-507-760
MolPort-003-666-287
NCGC00015970-01
NCGC00015970-02
NCGC00015970-03
NCGC00015970-08
NCGC00025268-01
NCGC00025268-02
NCGC00025268-03
NCGC00094349-01
NCGC00094349-02
NINDS_000601
Novo Sundac
Novo-Sundac
Novopharm Brand of Sulindac
Nu Pharm Brand of Sulindac
Nu Sulindac
Nu-Pharm Brand of Sulindac
Nu-Sulindac
Prestwick0_000073
Prestwick1_000073
Prestwick2_000073
Prestwick3_000073
Prestwick_456
Resin copal
S 8139
S2007_Selleck
S4429_SIAL
S8139_SIAL
S8139_SIGMA
SAM002554933
SBB058181
SMR000043852
SMR000326718
SPBio_001451
SPBio_002206
SPECTRUM1500556
STK802068
Spectrum2_001326
Spectrum3_001365
Spectrum4_000876
Spectrum5_001024
Spectrum_001026
Sulindac
Sulindac (JAN/USP/INN)
Sulindac [USAN:BAN:INN:JAN]
Sulindac sulfoxide
Sulindaco
Sulindaco [INN-Spanish]
Sulindacum
Sulindacum [INN-Latin]
Sulindal
Tocris-1707
UNII-184SNS8VUH
UNII-M5221THD3M
UNM-0000306136
Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid
[(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid
cMAP_000021
cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((P-methylsulfinyl)benzylidene)indene-3-acetic acid
cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid
sulindac
{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid
{5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid
18
Ursodeoxycholic acidapproved, investigationalPhase 2, Phase 395128-13-231401
Synonyms:
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oate
(3a,5b,7b)-3,7-dihydroxy-cholan-24-oic acid
(3a,5b,7b)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid
(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid
(3α,5β,7β)-3,7-dihydroxycholan-24-oic acid
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
128-13-2
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol
3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
3,7-Dihydroxycholan-24-oic acid
3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid
3-alpha,7-beta-Dihydroxycholanic acid
3-alpha,7-beta-Dioxycholanic acid
3a,7b-Dihydroxy-5b-cholan-24-oate
3a,7b-Dihydroxy-5b-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid
3alpha,7beta-Dihydroxy-5beta-cholanic acid
4-10-00-01604 (Beilstein Handbook Reference)
50809-41-1
5beta-Cholan-24-oic acid-3alpha,7beta-diol
5beta-Cholanic Acid-3alpha,7beta-diol
7-beta-Hydroxylithocholic acid
7beta-Hydroxylithocholic acid
80225-86-1
AB00513977
AC-18919
AC-2081
AC1L1LJH
Acide ursodesoxycholique
Acide ursodesoxycholique [INN-French]
Acido ursodeossicolico
Acido ursodeossicolico [Italian]
Acido ursodeoxicolico
Acido ursodeoxicolico [INN-Spanish]
Acidum ursodeoxycholicum
Acidum ursodeoxycholicum [INN-Latin]
Actigall
Actigall (TN)
Antigall
Arsacol
BB_NC-2372
BPBio1_001052
BRN 3219888
BSPBio_000956
C07880
C24H40O4
CCRIS 5502
CHEBI:9907
CHEMBL1551
CHEMBL73390
CID11516715
CID31401
CPD-10534
CPD000058403
Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-beta)- (9CI)
Cholit-ursan
D00734
DB01586
Delursan
Deoxyursocholic Acid
Destolit
Deursil
Dom-ursodiol c
EINECS 204-879-3
HMS1570P18
 
ISO-URSODEOXYCHOLIC ACID
IU5
LMST04010033
LS-53033
Litursol
Lyeton
MLS000028461
MLS001066373
MolPort-001-794-630
MolPort-005-932-884
NCGC00179363-01
NCI60_028904
NSC 657950
NSC 683769
PHL-ursodiol c
PMS-ursodiol c
Peptarom
Prestwick0_000958
Prestwick1_000958
Prestwick2_000958
Prestwick3_000958
S1643_Selleck
SAM002264653
SMP2_000012
SMR000058403
SPBio_003105
Sodium Ursodeoxycholate
Solutrat
U-9000
U0030
U5127_SIGMA
UDCA
UDCS
UNII-724L30Y2QR
URSODEOXYCHOLIC ACID
UrSO
Urosdesoxycholate
Urosdesoxycholic acid
Urosiol
Ursacholic Acid
Ursacol
Urso
Urso (TN)
Urso 250
Urso DS
Urso Forte
Ursobilin
Ursochol
Ursodamor
Ursodeoxy cholic acid
Ursodeoxycholate
Ursodeoxycholic acid
Ursodeoxycholic acid (JP15/INN)
Ursodeoxycholic acid, UDCA, Ursosan, Ursofalk, Urso Forte, Udiliv, Ursodiol
Ursodeoxycholicacid
Ursodesoxycholic acid
Ursodexycholate
Ursodexycholic Acid
Ursodexycholic acid
Ursodiol
Ursodiol (USP)
Ursodiol [USAN]
Ursofalk
Ursolvan
Ursosan
chenodeoxycholic acid
ursodeoxycholate
ursodiol
19
LoperamideapprovedPhase 314353179-11-63955
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
Apo-Loperamide
BAS 01889668
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
IDI1_000215
IDI1_033851
Imodium A-D
Imodium A-D Caplets
Ioperamide
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
 
KBio3_000202
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
Kaopectate II
L000709
LS-114352
Lopac-L-4762
Lopac0_000708
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
Loperamide (INN)
Loperamide Monohydrochloride
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamidum
Loperamidum [INN-Latin]
Lopéramide
Maalox Anti-Diarrheal
MolPort-001-969-016
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
NINDS_000215
Nu-Loperamide
Oprea1_109220
PMS-Loperamide
Pepto Diarrhea Control
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
Rho-Loperamide
SPBio_001816
SPBio_002187
ST095179
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
Spectrum_000374
Tocris-0840
UNII-6X9OC3H4II
loperamide
nchembio.559-comp8
nchembio.79-comp7
20DolutegravirapprovedPhase 31411051375-16-654726191
21Cholagogues and CholereticsPhase 2, Phase 3127
22Antiviral AgentsPhase 39732
23ImmunoglobulinsPhase 36045
24AntibodiesPhase 36045
25AntidiarrhealsPhase 3143
26Antiparasitic AgentsPhase 3, Phase 22127
27Antiprotozoal AgentsPhase 3, Phase 21986
28Integrase InhibitorsPhase 3408
29HIV Integrase InhibitorsPhase 3387
30Anti-Retroviral AgentsPhase 33232
31Anti-HIV AgentsPhase 33100
32Antibodies, MonoclonalPhase 33795
33ColaNutraceuticalPhase 2, Phase 3, Phase 11881
34Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 3969
35
OrnithineNutraceuticalPhase 3, Phase 2693184-13-26262, 389
Synonyms:
(+)-S-Ornithine
(+/-)-2,5-Diaminopentanoic acid monohydrochloride
(S)-2,5-Diaminopentanoate
(S)-2,5-Diaminopentanoic acid
(S)-Ornithine
(S)-a,D-Diaminovalerate
(S)-a,D-Diaminovaleric acid
2,5-Diaminopentanoic acid hydrochloride
5-Amino-L-Norvaline
D -2,5-Diaminopentanoic acid
D-Ornithine
DL -2,5-Diaminopentanoic acid
DL-ornithine
DL-ornithine HCL
DL-ornithine monohydrochloride
DL-ornithine, hydrochloride
 
L -2,5-Diaminopentanoic acid
L-(-)-Ornithine
L-Ornithine
L-Ornithine hydrochloride
L-Ornithine hydrochloride (van)
L-Ornithine monohydrochloride
L-Ornithine, monohydrochloride
L-Ornithine-carboxy-14C hydrochloride
MonohydrochlorideDL-Ornithine
Monohydrochloridel-Ornithine
Ornithine DL-form HCL
Ornithine DL-form monohydrochloride
Ornithine hydrochloride
Ornithine hydrochloride (van)
Ornithine monohydrochloride
Ornithine, hydrochloride (1:1)
Ornithine, monohydrochloride
Poly-L-ornithine hydrochloride
36
MetforminapprovedPhase 21746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
37
EverolimusapprovedPhase 1, Phase 21896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
38
Sirolimusapproved, investigationalPhase 1, Phase 2189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
39
Miconazoleapproved, investigational, vet_approvedPhase 1, Phase 2362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
40
Inulinapproved, nutraceuticalPhase 21029005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
41
Vitamin Aapproved, nutraceutical, vet_approvedPhase 246811103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
42Hypoglycemic AgentsPhase 25733
43Protein Kinase InhibitorsPhase 23612
44
Erlotinib HydrochloridePhase 2798183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
45Retinol palmitatePhase 2468
46Turmeric extractPhase 266
47
CurcuminPhase 2137458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
48Immunosuppressive AgentsPhase 1, Phase 212770
49Antibiotics, AntitubercularPhase 1, Phase 26972
50Antifungal AgentsPhase 1, Phase 23615

Interventional clinical trials:

(show top 50)    (show all 79)
idNameStatusNCT IDPhase
1Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisUnknown statusNCT02175914Phase 4
2Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted VersionNot yet recruitingNCT02354560Phase 4
3A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)TerminatedNCT00140894Phase 4
4Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control PatientsTerminatedNCT00151476Phase 4
5Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) PatientsUnknown statusNCT00134758Phase 2, Phase 3
6Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPACompletedNCT00510692Phase 2, Phase 3
7Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous PolyposisCompletedNCT00808743Phase 2, Phase 3
8Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove PolypsCompletedNCT00005094Phase 3
9Clinical Approaches to Ileal Pouch DysfunctionCompletedNCT00293553Phase 3
10Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep ApneaCompletedNCT01186926Phase 2, Phase 3
11Use of Post Operative Loperamide in Colorectal Patients After Diverting IleostomiesRecruitingNCT02263365Phase 3
12Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)Active, not recruitingNCT01483144Phase 3
13Compassionate Use of Ibalizumab for the Treatment of HIV InfectionNo longer availableNCT02028819Phase 3
14Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)TerminatedNCT00585312Phase 3
15Coxib-inhibition of Duodenal Polyp Growth in FAPTerminatedNCT00844727Phase 2, Phase 3
16A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)WithdrawnNCT01245816Phase 3
17Exisulind in Preventing Polyps in Patients With Familial Adenomatous PolyposisWithdrawnNCT00026468Phase 2, Phase 3
18Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous PolyposisUnknown statusNCT00319007Phase 2
19The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled StudyUnknown statusNCT01725490Phase 2
20A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsCompletedNCT01187901Phase 2
21Curcumin in Treating Patients With Familial Adenomatous PolyposisCompletedNCT00641147Phase 2
22Effects of Raw Versus Other Milk Sources on Lactose DigestionCompletedNCT01129791Phase 2
23A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type FibromatosisRecruitingNCT01265030Phase 1, Phase 2
24MLE4901 vs. Placebo for the Treatment of PCOSRecruitingNCT02865915Phase 2
25Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal CancersActive, not recruitingNCT00503035Phase 2
26Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerNot yet recruitingNCT02961374Phase 2
27Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous PolyposisTerminatedNCT00033371Phase 2
28Outpatient Neutropenic Diet StudyTerminatedNCT00947648Phase 2
29Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis PatientsWithdrawnNCT00248053Phase 2
30Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CWCompletedNCT02113202Phase 1
31Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)CompletedNCT00770991Phase 1
32Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous PolyposisCompletedNCT00685568Phase 1
33A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersCompletedNCT00813241Phase 1
34Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet ActionCompletedNCT02060396Phase 1
35Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard EndoscopyUnknown statusNCT00253812
36Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase PathwayUnknown statusNCT00498134
37Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal CancerUnknown statusNCT00675636
38Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical TrialUnknown statusNCT01839864
39Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?CompletedNCT01173250
40A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner SyndromeCompletedNCT01286662
41Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaCompletedNCT02162173
42Genetic Analysis of Hereditary Prostate CancerCompletedNCT00001469
43Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective StudyCompletedNCT01764503
44Oligogenic Determinism of Colorectal CancerCompletedNCT01057953
45Single Incision Laparoscopic Surgery in Treating Patients With Colorectal DiseaseCompletedNCT01656746
46Ingenio Device Algorithm StudyCompletedNCT01441583
47Cidofovir as a Treatment for Herpes Simplex in Patients With AIDSCompletedNCT00002181
48Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance ProgramRecruitingNCT02747862
49Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)RecruitingNCT02656134
50Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis PatientsRecruitingNCT01604564

Search NIH Clinical Center for Adenomatous Polyposis Coli

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: adenomatous polyposis coli

Genetic Tests for Adenomatous Polyposis Coli

About this section

Genetic tests related to Adenomatous Polyposis Coli:

id Genetic test Affiliating Genes
1 Familial Adenomatous Polyposis 127
2 Familial Multiple Polyposis Syndrome27
3 Gardner Syndrome27 24 APC
4 Brain Tumor-Polyposis Syndrome 227
5 Familial Adenomatous Polyposis24 APC

Anatomical Context for Adenomatous Polyposis Coli

About this section

MalaCards organs/tissues related to Adenomatous Polyposis Coli:

36
Colon, Skin, Thyroid, Brain, Liver, Bone, Adrenal gland

Publications for Adenomatous Polyposis Coli

About this section

Articles related to Adenomatous Polyposis Coli:

(show top 50)    (show all 300)
idTitleAuthorsYear
1
Insulin signaling regulates a functional interaction between Adenomatous Polyposis Coli (APC) and cytoplasmic dynein. (28057765)
2017
2
Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. (26760960)
2016
3
Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells. (26609171)
2016
4
Tumour Suppressor Adenomatous Polyposis Coli (APC) localisation is regulated by both Kinesin-1 and Kinesin-2. (27272132)
2016
5
Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. (27028212)
2016
6
Deep vein thrombosis in a patient of adenomatous polyposis coli treated successfully with aspirin: A case report. (27386068)
2016
7
Adenomatous polyposis coli (APC) regulates miR17-92 cluster through I^-catenin pathway in colorectal cancer. (26804172)
2016
8
Cribriform morular variant of papillary thyroid carcinoma: Cytomorphology, differential diagnosis and diagnostic implications in patients with adenomatous polyposis coli. (28028343)
2016
9
miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli. (27595705)
2016
10
Characterization of Adenomatous Polyposis Coli Protein Dynamics and Localization at the Centrosome. (27144584)
2016
11
Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. (27798265)
2016
12
Adenomatous polyposis coli regulates radial axonal sorting and myelination in the PNS. (27226321)
2016
13
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli. (27334689)
2016
14
Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. (26970738)
2016
15
A novel pathogenic large germline deletion in adenomatous polyposis coli gene in a Chinese family with familial adenomatous polyposis. (27391059)
2016
16
Adenomatous polyposis coli mutants dominantly activate Hsf1-dependent cell stress pathways through inhibition of microtubule dynamics. (26320184)
2015
17
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice. (26139199)
2015
18
Adenomatous Polyposis Coli Protein Deletion in Efferent Olivocochlear Neurons Perturbs Afferent Synaptic Maturation and Reduces the Dynamic Range of Hearing. (26085645)
2015
19
Adenomatous polyposis coli (APC)-induced apoptosis of HT29 colorectal cancer cells depends on mitochondrial oxidative metabolism. (26004395)
2015
20
Expression and mutation pattern of I^-catenin and adenomatous polyposis coli in colorectal cancer patients. (25660336)
2015
21
High-resolution Melting Analysis for Gene Scanning of Adenomatous Polyposis Coli (APC) Gene With Oral Squamous Cell Carcinoma Samples. (26447891)
2015
22
MicroRNA-663 activates the canonical Wnt signaling through the adenomatous polyposis coli suppression. (26028359)
2015
23
Residual rectal mucosa after stapled vs. handsewn ileal J-pouch-anal anastomosis in patients with familial adenomatous polyposis coli (FAP)--a critical issue. (25586093)
2015
24
Adenomatous Polyposis Coli Mutation Leads to Myopia Development in Mice. (26495845)
2015
25
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. (26334567)
2015
26
Association of CD24 and the adenomatous polyposis coli gene polymorphisms with oral lichen planus. (26187149)
2015
27
Tissue-Specific Effects of Reduced I^-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium. (26528816)
2015
28
Mesenchymal adenomatous polyposis coli plays critical and diverse roles in regulating lung development. (26092405)
2015
29
A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. (26311738)
2015
30
different Roles for the axin interactions with the SAMP versus the second twenty amino acid repeat of adenomatous polyposis coli. (24722208)
2014
31
5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. (25460919)
2014
32
Aspirin augments the expression of Adenomatous Polyposis Coli protein by suppression of IKKI^. (24613833)
2014
33
Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-I^-catenin signalling. (24251807)
2014
34
Low-grade neuroendocrine tumors arising in intestinal adenomas: evidence for alterations in the adenomatous polyposis coli/I^-catenin pathway. (25149552)
2014
35
The effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (I^-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin). (24390805)
2014
36
Adenomatous polyposis coli gene large deletions in Iranian patients with familial adenomatous polyposis. (25494137)
2014
37
Two Chinese pedigrees for adenomatous polyposis coli: new mutations at codon 1309 and predisposition to phenotypic variations. (24664542)
2014
38
Minimal access laparoscopic surgery for treatment of ulcerative colitis and familial adenomatous polyposis coli in children and adolescents. (25247476)
2014
39
N-terminal truncation mutations of adenomatous polyposis coli are associated with primary cilia defects. (25150829)
2014
40
Early postoperative complications after stapled vs handsewn restorative proctocolectomy with ileal pouch-anal anastomosis in 148 patients with familial adenomatous polyposis coli: a matched-pair analysis. (23941307)
2014
41
Desmoid tumour biology in patients with familial adenomatous polyposis coli. (23334997)
2013
42
Anal transitional zone neoplasia in patients with familial adenomatous polyposis coli syndrome. (23739184)
2013
43
Functional comparison of human adenomatous polyposis coli (APC) and APC-like in targeting beta-catenin for degradation. (23840886)
2013
44
Large extent of disorder in Adenomatous Polyposis Coli offers a strategy to guard Wnt signalling against point mutations. (24130866)
2013
45
miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. (23087084)
2013
46
Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms. (24139208)
2013
47
Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the Adenomatous polyposis coli gene. (24005794)
2013
48
HectD1 E3 ligase modifies adenomatous polyposis coli (APC) with polyubiquitin to promote the APC-axin interaction. (23277359)
2013
49
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. (23555190)
2013
50
Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis. (22120905)
2012

Variations for Adenomatous Polyposis Coli

About this section

UniProtKB/Swiss-Prot genetic disease variations for Adenomatous Polyposis Coli:

70 (show all 11)
id Symbol AA change Variation ID SNP ID
1APCp.Ser171IleVAR_005032
2APCp.Arg414CysVAR_005033rs137854567
3APCp.Ser784ThrVAR_005034
4APCp.Glu911GlyVAR_005038
5APCp.Pro1176LeuVAR_005044
6APCp.Thr1313AlaVAR_005051rs863225349
7APCp.Arg1348TrpVAR_005053
8APCp.Ser2621CysVAR_005056rs72541816
9APCp.Leu2839PheVAR_005057
10APCp.Ser722GlyVAR_009614
11APCp.Ala1184ProVAR_009616

Clinvar genetic disease variations for Adenomatous Polyposis Coli:

5 (show all 151)
id Gene Variation Type Significance SNP ID Assembly Location
1APCNM_000038.5(APC): c.1213C> T (p.Arg405Ter)SNVPathogenicrs587779780GRCh38Chr 5, 112819245: 112819245
2APCNM_000038.5(APC): c.2413C> T (p.Arg805Ter)SNVPathogenicrs587779783GRCh38Chr 5, 112838007: 112838007
3APCNM_000038.5(APC): c.3088A> T (p.Lys1030Ter)SNVPathogenicrs587779786GRCh38Chr 5, 112838682: 112838682
4MUTYHNM_001128425.1(MUTYH): c.1227_1228dupGG (p.Glu410Glyfs)duplicationPathogenicrs587780078GRCh37Chr 1, 45797187: 45797188
5MUTYHNM_001128425.1(MUTYH): c.1437_1439delGGA (p.Glu480del)deletionPathogenicrs587778541GRCh37Chr 1, 45796891: 45796893
6MUTYHNM_001128425.1(MUTYH): c.55C> T (p.Arg19Ter)SNVPathogenicrs587780088GRCh37Chr 1, 45800165: 45800165
7MUTYHNM_001128425.1(MUTYH): c.1147delC (p.Ala385Profs)deletionPathogenicrs587778536GRCh37Chr 1, 45797372: 45797372
8MUTYHNM_001128425.1(MUTYH): c.933+3A> CSNVPathogenicrs587780751GRCh37Chr 1, 45797835: 45797835
9APCNM_000038.5(APC): c.5934_5937delAAAC (p.Asn1979Thrfs)deletionPathogenicrs587781330GRCh38Chr 5, 112841528: 112841531
10MUTYHNM_001128425.1(MUTYH): c.734G> A (p.Arg245His)SNVLikely pathogenic, Pathogenicrs140342925GRCh38Chr 1, 45332445: 45332445
11APCNM_000038.5(APC): c.637C> T (p.Arg213Ter)SNVPathogenicrs587781392GRCh38Chr 5, 112780895: 112780895
12MUTYHNM_001128425.1(MUTYH): c.1187-2A> GSNVLikely pathogenic, Pathogenicrs587781628GRCh37Chr 1, 45797230: 45797230
13APCNM_000038.5(APC): c.2004delC (p.Leu669Terfs)deletionPathogenicrs587782303GRCh37Chr 5, 112173295: 112173295
14APCNM_000038.5(APC): c.426_427delAT (p.Leu143Alafs)deletionPathogenicrs587782557GRCh38Chr 5, 112775632: 112775633
15MUTYHNM_001128425.1(MUTYH): c.1214C> T (p.Pro405Leu)SNVPathogenicrs529008617GRCh37Chr 1, 45797201: 45797201
16APCNM_000038.5(APC): c.3286C> T (p.Gln1096Ter)SNVPathogenicrs587783029GRCh38Chr 5, 112838880: 112838880
17APCNM_000038.5(APC): c.2107delG (p.Ala703Glnfs)deletionPathogenicrs587783030GRCh38Chr 5, 112837701: 112837701
18APCNM_000038.5(APC): c.4666delA (p.Thr1556Leufs)deletionPathogenicrs587783031GRCh38Chr 5, 112840260: 112840260
19APCNM_000038.5(APC): c.3814delT (p.Ser1272Glnfs)deletionPathogenicrs587783033GRCh38Chr 5, 112839408: 112839408
20APCNM_000038.5(APC): c.1744-2A> GSNVPathogenicrs587783035GRCh38Chr 5, 112834949: 112834949
21APCNC_000005.10: g.(?_112754891)_(112844071_?)deldeletionPathogenicGRCh37Chr 5, 112090588: 112179768
22APCNM_000038.5(APC): c.4255delA (p.Ser1419Alafs)deletionLikely pathogenicrs727504420GRCh37Chr 5, 112175546: 112175546
23APCNM_000038.5(APC): c.477delC (p.Tyr159Terfs)deletionPathogenicrs730880250GRCh37Chr 5, 112111380: 112111380
24APCNM_000038.5(APC): c.1312+3_1312+4delATdeletionPathogenicrs730881228GRCh38Chr 5, 112819347: 112819348
25APCNM_000038.5(APC): c.5490_5493delTGAA (p.Asn1830Lysfs)deletionPathogenicrs730881273GRCh38Chr 5, 112841084: 112841087
26MUTYHNM_001128425.1(MUTYH): c.545G> A (p.Arg182His)SNVPathogenicrs143353451GRCh38Chr 1, 45332794: 45332794
27MUTYHNM_001128425.1(MUTYH): c.857G> A (p.Gly286Glu)SNVLikely pathogenic, Pathogenicrs730881833GRCh38Chr 1, 45332242: 45332242
28APCNM_000038.5(APC): c.3149delC (p.Ala1050Glufs)deletionPathogenicrs730882135GRCh38Chr 5, 112838743: 112838743
29MUTYHNM_001128425.1(MUTYH): c.325C> T (p.Arg109Trp)SNVLikely pathogenic, Pathogenicrs765123255GRCh37Chr 1, 45799108: 45799108
30APCNM_000038.5(APC): c.70C> T (p.Arg24Ter)SNVPathogenicrs145945630GRCh37Chr 5, 112090657: 112090657
31MUTYHNM_001128425.1(MUTYH): c.309G> A (p.Trp103Ter)SNVPathogenicrs748170941GRCh37Chr 1, 45799124: 45799124
32APCNM_000038.5(APC): c.847C> T (p.Arg283Ter)SNVPathogenicrs786201856GRCh37Chr 5, 112151204: 112151204
33MUTYHNM_001128425.1(MUTYH): c.721C> T (p.Arg241Trp)SNVLikely pathogenic, Pathogenicrs34126013GRCh37Chr 1, 45798130: 45798130
34APCNM_000038.5(APC): c.3471_3474delGAGA (p.Glu1157Aspfs)deletionPathogenicrs786203020GRCh37Chr 5, 112174762: 112174765
35MUTYHNM_001128425.1(MUTYH): c.799C> T (p.Gln267Ter)SNVPathogenicrs786203115GRCh37Chr 1, 45797972: 45797972
36MUTYHNM_001128425.1(MUTYH): c.544C> T (p.Arg182Cys)SNVLikely pathogenic, Pathogenicrs747993448GRCh37Chr 1, 45798467: 45798467
37APCNM_000038.5(APC): c.925G> T (p.Gly309Ter)SNVPathogenicrs786204118GRCh38Chr 5, 112815585: 112815585
38APCNM_000038.5(APC): c.3830T> G (p.Leu1277Ter)SNVPathogenicrs786204169GRCh37Chr 5, 112175121: 112175121
39APCNM_000038.5(APC): c.4175C> A (p.Ser1392Ter)SNVPathogenicrs786204170GRCh37Chr 5, 112175466: 112175466
40APCNM_000038.5(APC): c.1262G> A (p.Trp421Ter)SNVPathogenicrs559510809GRCh38Chr 5, 112819294: 112819294
41APCNM_000038.5(APC): c.2563_2564delGA (p.Glu855Thrfs)deletionPathogenicrs794727160GRCh37Chr 5, 112173854: 112173855
42APCNM_000038.5(APC): c.4348C> T (p.Arg1450Ter)SNVPathogenicrs121913332GRCh37Chr 5, 112175639: 112175639
43APCNM_000038.5(APC): c.1072C> T (p.Gln358Ter)SNVPathogenicrs863224455GRCh38Chr 5, 112819104: 112819104
44APCNM_000038.5(APC): c.1409-?_*(1_?)deldeletionPathogenicGRCh38Chr 5, 112827108: 112844127
45APCNM_000038.5(APC): c.2626C> T (p.Arg876Ter)SNVPathogenicrs121913333GRCh38Chr 5, 112838220: 112838220
46APCNM_000038.5(APC): c.3921_3924delAAAA (p.Ile1307Metfs)deletionPathogenicrs863224457GRCh38Chr 5, 112839515: 112839518
47APCNM_000038.5(APC): c.423G> T (p.Arg141Ser)SNVPathogenicrs863224458GRCh37Chr 5, 112111326: 112111326
48APCNM_000038.5(APC): c.791delA (p.Gly265Glufs)deletionPathogenicrs863224459GRCh37Chr 5, 112137037: 112137037
49MUTYHNM_001128425.1(MUTYH): c.1214_1224delCGTCCGTGACC (p.Pro405Leufs)deletionPathogenicrs863224501GRCh37Chr 1, 45797191: 45797201
50MUTYHNM_001128425.1(MUTYH): c.1474A> T (p.Lys492Ter)SNVPathogenicrs863224502GRCh37Chr 1, 45796856: 45796856
51MUTYHNM_001128425.1(MUTYH): c.349-?_*(1_?)deldeletionPathogenicGRCh37Chr 1, 45794977: 45798996
52APCNM_000038.5(APC): c.1886dupT (p.Leu629Phefs)duplicationPathogenicrs863224817GRCh38Chr 5, 112835093: 112835093
53APCNM_000038.5(APC): c.453delA (p.Glu152Lysfs)deletionPathogenicrs863224820GRCh38Chr 5, 112775659: 112775659
54APCNM_000038.5(APC): c.1312+3A> GSNVLikely pathogenic, Pathogenicrs863225311GRCh37Chr 5, 112155044: 112155044
55APCNM_000038.5(APC): c.1892_1904delTTATTGAAAGTGGinsAAT (p.Ile631Lysfs)indelLikely pathogenic, Pathogenicrs863225319GRCh38Chr 5, 112835099: 112835111
56APCNM_000038.5(APC): c.1972_1975delGAGA (p.Glu658Thrfs)deletionPathogenicrs863225322GRCh37Chr 5, 112173263: 112173266
57APCNM_000038.5(APC): c.423-?_531+?deldeletionPathogenicChr na, -1: -1
58APCNM_000038.5(APC): c.5145delC (p.Asp1715Glufs)deletionPathogenicrs863225363GRCh38Chr 5, 112840739: 112840739
59APCNM_000038.5(APC): c.645+1G> ASNVLikely pathogenic, Pathogenicrs863225370GRCh37Chr 5, 112116601: 112116601
60APCNM_000038.5(APC): c.3404_3405delAT (p.Tyr1135Terfs)deletionPathogenicrs864622086GRCh37Chr 5, 112174695: 112174696
61APCNM_000038.5(APC): c.3595_3596delAA (p.Lys1199Glufs)deletionPathogenicrs864622106GRCh37Chr 5, 112174886: 112174887
62APCNM_000038.5(APC): c.5826_5829delCAGA (p.Asp1942Glufs)deletionPathogenicrs864622228GRCh38Chr 5, 112841420: 112841423
63APCNM_000038.5(APC): c.3925_3928delGAAA (p.Glu1309Argfs)deletionPathogenicrs876659647GRCh37Chr 5, 112175216: 112175219
64MUTYHNM_001128425.1(MUTYH): c.389-1G> CSNVLikely pathogenic, Pathogenicrs372267274GRCh37Chr 1, 45798843: 45798843
65APCNM_000038.5(APC): c.4717delG (p.Glu1573Lysfs)deletionPathogenicrs878853217GRCh38Chr 5, 112840311: 112840311
66APCNM_000038.5(APC): c.-85-?_*2113+?deldeletionPathogenicChr na, -1: -1
67APCNM_000038.5(APC): c.1743+1G> ASNVLikely pathogenicrs761458613GRCh38Chr 5, 112828973: 112828973
68APCNM_000038.5(APC): c.1866_1867delCCinsAT (p.Tyr622Ter)indelPathogenicrs878853419GRCh38Chr 5, 112835073: 112835074
69APCNM_000038.5(APC): c.1875_1878delGACA (p.Asn627Leufs)deletionPathogenicrs878853420GRCh38Chr 5, 112835082: 112835085
70APCNM_000038.5(APC): c.2031_2034delCAGT (p.Ser678Metfs)deletionPathogenicrs878853422GRCh37Chr 5, 112173322: 112173325
71APCNM_000038.5(APC): c.2314delA (p.Thr772Leufs)deletionPathogenicrs878853426GRCh38Chr 5, 112837908: 112837908
72APCNM_000038.5(APC): c.249delT (p.Gly84Glufs)deletionPathogenicrs878853428GRCh38Chr 5, 112767217: 112767217
73APCNM_000038.5(APC): c.2795C> G (p.Ser932Ter)SNVPathogenicrs878853432GRCh37Chr 5, 112174086: 112174086
74APCNM_000038.5(APC): c.3196delA (p.Arg1066Aspfs)deletionPathogenicrs878853436GRCh38Chr 5, 112838790: 112838790
75APCNM_000038.5(APC): c.3340C> T (p.Arg1114Ter)SNVPathogenicrs121913331GRCh38Chr 5, 112838934: 112838934
76APCNM_000038.5(APC): c.3391C> T (p.Gln1131Ter)SNVPathogenicrs878853438GRCh38Chr 5, 112838985: 112838985
77APCNM_000038.5(APC): c.448A> T (p.Lys150Ter)SNVPathogenicrs878853444GRCh37Chr 5, 112111351: 112111351
78APCNM_000038.5(APC): c.4701delA (p.Asp1568Metfs)deletionPathogenicrs878853449GRCh37Chr 5, 112175992: 112175992
79APCNM_000038.5(APC): c.476dupA (p.Tyr159Terfs)duplicationPathogenicrs878853451GRCh37Chr 5, 112111379: 112111379
80APCNM_000038.5(APC): c.4987G> T (p.Glu1663Ter)SNVPathogenicrs758987855GRCh38Chr 5, 112840581: 112840581
81APCNM_000038.5(APC): c.5025dupT (p.Arg1676Terfs)duplicationPathogenicrs878853454GRCh37Chr 5, 112176316: 112176316
82APCNM_000038.5(APC): c.5917delA (p.Ser1973Valfs)deletionPathogenicrs878853458GRCh37Chr 5, 112177208: 112177208
83APCNM_000038.5(APC): c.595dupG (p.Ala199Glyfs)duplicationPathogenicrs878853459GRCh37Chr 5, 112116550: 112116550
84APCNM_000038.5(APC): c.6610C> T (p.Arg2204Ter)SNVLikely pathogenicrs752654519GRCh38Chr 5, 112842204: 112842204
85APCNM_000038.5(APC): c.934-?_*2113+?deldeletionPathogenicChr na, -1: -1
86MUTYHNM_001128425.1(MUTYH): c.1435G> T (p.Glu479Ter)SNVPathogenicrs376790729GRCh37Chr 1, 45796895: 45796895
87MUTYHNM_001128425.1(MUTYH): c.333dupA (p.Pro112Thrfs)duplicationPathogenicrs878854189GRCh37Chr 1, 45799100: 45799100
88APCNM_001127511.2(APC): c.-191T> CSNVPathogenicrs879253783GRCh38Chr 5, 112707527: 112707527
89APCNM_001127511.2(APC): c.-192A> GSNVPathogenicrs879253784GRCh38Chr 5, 112707526: 112707526
90APCNM_001127511.2(APC): c.-192A> TSNVPathogenicrs879253784GRCh38Chr 5, 112707526: 112707526
91APCNM_001127511.2(APC): c.-190G> ASNVPathogenicrs879253785GRCh38Chr 5, 112707528: 112707528
92APCNM_000038.5(APC): c.-18-?_834+?dupduplicationLikely pathogenicChr na, -1: -1
93APCNM_001127510.2(APC): c.2483delC (p.Thr828Ilefs)deletionPathogenicrs886042600GRCh38Chr 5, 112838077: 112838077
94MUTYHNM_001128425.1(MUTYH): c.348+33_*210delinsTAindelPathogenicGRCh38Chr 1, 45329096: 45333380
95MUTYHNM_001128425.1(MUTYH): c.1418C> A (p.Ala473Asp)SNVPathogenicrs200844166GRCh37Chr 1, 45796912: 45796912
96MUTYHNM_001128425.1(MUTYH): c.733C> T (p.Arg245Cys)SNVLikely pathogenic, Pathogenicrs200495564GRCh37Chr 1, 45798118: 45798118
97MUTYHNM_001128425.1(MUTYH): c.934-2A> GSNVLikely pathogenic, Pathogenicrs77542170GRCh37Chr 1, 45797760: 45797760
98APCNM_000038.5(APC): c.1917dupA (p.Arg640Thrfs)duplicationLikely pathogenicrs397515732GRCh37Chr 5, 112170821: 112170821
99APCNM_000038.5(APC): c.3162delC (p.His1054Glnfs)deletionPathogenicrs397515733GRCh37Chr 5, 112174453: 112174453
100APCNM_000038.5(APC): c.694C> T (p.Arg232Ter)SNVPathogenicrs397515734GRCh37Chr 5, 112128191: 112128191
101APCNM_000038.5(APC): c.896_897delCT (p.Ser299Cysfs)deletionPathogenicrs397515735GRCh37Chr 5, 112151253: 112151254
102MUTYHNM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys)SNVPathogenicrs34612342GRCh37Chr 1, 45798475: 45798475
103MUTYHNM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp)SNVPathogenicrs36053993GRCh37Chr 1, 45797228: 45797228
104MUTYHNM_001128425.1(MUTYH): c.1461delC (p.Thr488Profs)deletionPathogenicrs587776618GRCh37Chr 1, 45796869: 45796869
105MUTYHNM_001128425.1(MUTYH): c.312C> A (p.Tyr104Ter)SNVPathogenicrs121908380GRCh37Chr 1, 45799121: 45799121
106MUTYHNM_001128425.1(MUTYH): c.1438G> T (p.Glu480Ter)SNVPathogenicrs121908381GRCh37Chr 1, 45796892: 45796892
107APCNM_000038.5(APC): c.730_731delAG (p.Arg244Valfs)deletionPathogenicrs387906228GRCh37Chr 5, 112136976: 112136977
108APCNM_000038.5(APC): c.1369delT (p.Ser457Hisfs)deletionPathogenicrs387906229GRCh37Chr 5, 112157649: 112157649
109APCNM_000038.5(APC): c.1500T> G (p.Tyr500Ter)SNVPathogenicrs387906230GRCh37Chr 5, 112162896: 112162896
110APCNM_000038.5(APC): c.904C> T (p.Arg302Ter)SNVPathogenicrs137854568GRCh37Chr 5, 112151261: 112151261
111APCNM_000038.5(APC): c.839C> G (p.Ser280Ter)SNVPathogenicrs137854569GRCh37Chr 5, 112151196: 112151196
112APCNM_000038.5(APC): c.2138C> G (p.Ser713Ter)SNVPathogenicrs137854570GRCh37Chr 5, 112173429: 112173429
113APCNM_000038.5(APC): c.4012C> T (p.Gln1338Ter)SNVPathogenicrs121913327GRCh37Chr 5, 112175303: 112175303
114APCNM_000038.5(APC): c.509_512delATAG (p.Asp170Valfs)deletionPathogenicrs387906231GRCh37Chr 5, 112111412: 112111415
115APCNM_000038.5(APC): c.1069dupA (p.Ile357Asnfs)duplicationPathogenicrs387906232GRCh37Chr 5, 112154798: 112154798
116APCNM_000038.5(APC): c.1621C> T (p.Gln541Ter)SNVPathogenicrs137854572GRCh37Chr 5, 112163698: 112163698
117APCNM_000038.5(APC): c.1660C> T (p.Arg554Ter)SNVPathogenicrs137854573GRCh37Chr 5, 112164586: 112164586
118APCNM_000038.5(APC): c.1690C> T (p.Arg564Ter)SNVPathogenicrs137854574GRCh37Chr 5, 112164616: 112164616
119APCNM_000038.5(APC): c.1885_1886insA (p.Leu629Tyrfs)insertionPathogenicrs387906233GRCh37Chr 5, 112170789: 112170790
120APCNM_000038.5(APC): c.2805C> A (p.Tyr935Ter)SNVPathogenicrs137854575GRCh37Chr 5, 112174096: 112174096
121APCNM_000038.5(APC): c.4393_4394delAG (p.Ser1465Trpfs)deletionPathogenicrs387906234GRCh37Chr 5, 112175684: 112175685
122APCNM_000038.5(APC): c.470G> A (p.Trp157Ter)SNVPathogenicrs137854576GRCh37Chr 5, 112111373: 112111373
123APCNM_000038.5(APC): c.643C> T (p.Gln215Ter)SNVPathogenicrs137854577GRCh37Chr 5, 112116598: 112116598
124APCNC_000005.10: g.112836913_112908314del71402deletionPathogenicGRCh37Chr 5, 112172610: 112244011
125APCNM_000038.5(APC): c.3927_3931delAAAGA (p.Glu1309Aspfs)deletionPathogenicrs121913224GRCh37Chr 5, 112175218: 112175222
126APCNM_000038.5(APC): c.5942delA (p.Asn1981Ilefs)deletionPathogenicrs397509433GRCh37Chr 5, 112177233: 112177233
127APCNM_000038.5(APC): c.5582_5585delCTTT (p.Ser1861Terfs)deletionPathogenicrs587776520GRCh38Chr 5, 112841176: 112841179
128APCNM_000038.5(APC): c.3920T> A (p.Ile1307Lys)SNVPathogenic, risk factorrs1801155GRCh37Chr 5, 112175211: 112175211
129APCNM_000038.5(APC): c.4611_4612delAG (p.Glu1538Ilefs)deletionPathogenicrs387906236GRCh37Chr 5, 112175902: 112175903
130APCNM_000038.5(APC): c.1495C> T (p.Arg499Ter)SNVPathogenicrs137854580GRCh37Chr 5, 112162891: 112162891
131APCAPC, TYR486TERSNVPathogenicChr na, -1: -1
132APCNM_000038.5(APC): c.1311_1312+1delAAGdeletionPathogenicrs397514030GRCh37Chr 5, 112155040: 112155042
133APCNM_000038.5(APC): c.1098_1099delCT (p.Ser367Cysfs)deletionPathogenicrs387906237GRCh37Chr 5, 112154827: 112154828
134APCNM_000038.5(APC): c.1192_1193delAA (p.Lys398Glufs)deletionPathogenicrs387906238GRCh37Chr 5, 112154921: 112154922
135APCNM_000038.5(APC): c.937_938delGA (p.Glu313Asnfs)deletionPathogenicrs387906239GRCh37Chr 5, 112154666: 112154667
136APCNM_000038.5(APC): c.2093T> A (p.Leu698Ter)SNVPathogenicrs137854582GRCh37Chr 5, 112173384: 112173384
137APCAPC deletiondeletionPathogenicGRCh37Chr 5, 112043201: 112181937
138APCNM_000038.5(APC): c.423-1G> ASNVPathogenicrs397514031GRCh37Chr 5, 112111325: 112111325
139APCAPC, 11-BP INS, NT1060insertionPathogenicChr na, -1: -1
140APCNM_000038.5(APC): c.622C> T (p.Gln208Ter)SNVPathogenicrs137854583GRCh37Chr 5, 112116577: 112116577
141APCNG_008481.4: g.(?_150033)_(158719_?)deldeletionPathogenicGRCh38Chr 5, 112837553: 112846239
142APCAPC, 5-BP DEL, NT3221deletionPathogenicChr na, -1: -1
143APCNM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs)deletionPathogenicrs587779352GRCh37Chr 5, 112174474: 112174478
144APCNM_000038.5(APC): c.3202_3205delTCAA (p.Ser1068Glyfs)deletionPathogenicrs587779353GRCh37Chr 5, 112174493: 112174496
145APCNM_000038.5(APC): c.1659G> A (p.Trp553Ter)SNVPathogenicrs398123116GRCh37Chr 5, 112164585: 112164585
146APCNM_000038.5(APC): c.2365C> T (p.Gln789Ter)SNVPathogenicrs398123117GRCh37Chr 5, 112173656: 112173656
147APCNM_000038.5(APC): c.2547_2550delTAGA (p.Asp849Glufs)deletionPathogenicrs398123118GRCh37Chr 5, 112173838: 112173841
148APCNM_000038.5(APC): c.2731G> T (p.Glu911Ter)SNVPathogenicrs398123119GRCh37Chr 5, 112174022: 112174022
149APCNM_000038.5(APC): c.2805delC (p.Tyr935Terfs)deletionPathogenicrs398123120GRCh37Chr 5, 112174096: 112174096
150APCNM_000038.5(APC): c.3982C> T (p.Gln1328Ter)SNVPathogenicrs398123121GRCh37Chr 5, 112175273: 112175273
151APCNM_000038.5(APC): c.4473dupT (p.Ala1492Cysfs)duplicationPathogenicrs398123122GRCh37Chr 5, 112175764: 112175764

Expression for genes affiliated with Adenomatous Polyposis Coli

About this section
Search GEO for disease gene expression data for Adenomatous Polyposis Coli.

Pathways for genes affiliated with Adenomatous Polyposis Coli

About this section

Pathways related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show top 50)    (show all 52)
idSuper pathwaysScoreTop Affiliating Genes
110.1CDH1, CTNNB1
29.9AXIN1, CTNNB1, MAPRE1
39.8CCND1, CDH1, CTNNB1
4
Show member pathways
9.8MLH1, MSH2, TP53
59.8CTNNB1, MYC, TP53
6
Show member pathways
9.8MLH1, MSH2, MYC
79.7CCND1, CTNNB1, GSK3B
89.7CCND1, MYC, PTGS2
99.7CDH1, CTNNB1, MAPRE1, MAPRE2
109.7AXIN1, GSK3B, MYC
119.7APC, AXIN1, CTNNB1, GSK3B
129.7CCND1, MYC, TP53
139.7CCND1, MYC, TP53
149.7CCND1, MYC, TP53
159.7APC, MLH1, MSH2, TP53
16
Show member pathways
9.6AXIN1, AXIN2, CTNNB1, GSK3B
179.6GSK3B, MYC, TP53
18
Show member pathways
9.6APC, CDH1, CTNNB1, GSK3B
19
Show member pathways
9.5CCND1, MLH1, MSH2, TP53
209.5CCND1, CTNNB1, MYC, TP53
219.5CCND1, MYC, PTGS2, TP53
22
Show member pathways
9.5CCND1, CTNNB1, GSK3B, MYC
239.4APC, AXIN1, CDH1, CTNNB1, GSK3B
249.4APC, AXIN1, CDH1, CTNNB1, GSK3B
259.4CCND1, CDH1, MYC, TP53
26
Show member pathways
9.4CCND1, GSK3B, MYC, TP53
27
Show member pathways
9.4CCND1, GSK3B, MYC, TP53
28
Show member pathways
9.4CCND1, GSK3B, MYC, TP53
299.3CCND1, CDH1, CTNNB1, MYC, TP53
30
Show member pathways
9.3CCND1, CDH1, CTNNB1, GSK3B, TP53
319.2CCND1, CTNNB1, GSK3B, MYC, TP53
329.2APC, AXIN2, CCND1, CDH1, CTNNB1, MYC
33
Show member pathways
9.2APC, CDH1, CTNNB1, GSK3B, PTGS2, TP53
349.2APC, APC2, CCND1, MYC, PTGS2, TP53
359.2APC, CCND1, CTNNB1, MYC, PTGS2, TP53
369.2CCND1, MAPRE1, MLH1, MSH2, MUTYH, TP53
379.2AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
389.1AXIN1, AXIN2, CCND1, CTNNB1, MYC, TP53
39
Show member pathways
9.1CCND1, CDH1, GSK3B, MYC, TP53
409.1APC, AXIN1, CCND1, CTNNB1, GSK3B, MYC
419.1AXIN1, AXIN2, CDH1, CTNNB1, GSK3B, MYC
429.1APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
43
Show member pathways
9.0AMER1, APC, AXIN1, CTNNB1, GSK3B, MYC
449.0CCND1, CDH1, CTNNB1, MSH2, MYC, TP53
458.9APC, APC2, CCND1, CTNNB1, GSK3B, MYC
46
Show member pathways
8.9AMER1, APC, AXIN1, AXIN2, CTNNB1, GSK3B
478.9APC, AXIN1, CCND1, CTNNB1, GSK3B, MYC
488.6APC, APC2, AXIN1, AXIN2, CCND1, CDH1
498.4APC, AXIN1, CCND1, CDH1, CTNNB1, GSK3B
508.1APC, AXIN2, CCND1, CDH1, CTNNB1, GSK3B

GO Terms for genes affiliated with Adenomatous Polyposis Coli

About this section

Cellular components related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1cell projection membraneGO:003125311.0CTNNB1, MAPRE1
2apical junction complexGO:004329610.9CDH1, CTNNB1
3chiasmaGO:000571210.9MLH1, PMS1
4flotillin complexGO:001660010.9CDH1, CTNNB1
5MutLalpha complexGO:003238910.9MLH1, PMS1
6cell cortexGO:000593810.7APC, AXIN1, AXIN2, CTNNB1
7catenin complexGO:001634210.6APC, APC2, CDH1, CTNNB1
8microtubule cytoskeletonGO:001563010.6APC2, AXIN2, MAPRE1, MAPRE2
9lateral plasma membraneGO:001632810.6APC, AXIN1, CDH1, CTNNB1
10cytoplasmic microtubuleGO:000588110.4APC, APC2, AXIN1, AXIN2, MAPRE1
11centrosomeGO:000581310.3APC, AXIN2, CTNNB1, GSK3B, MAPRE1
12lamellipodiumGO:003002710.2APC, CDH1, CTNNB1, MCC, SPATA13
13beta-catenin destruction complexGO:003087710.2APC, APC2, AXIN1, AXIN2, CTNNB1, GSK3B
14Wnt signalosomeGO:19909099.9APC, CTNNB1, GSK3B
15nucleoplasmGO:00056548.9APC, AXIN2, CCND1, CTNNB1, MCC, MLH1
16cytoplasmGO:00057378.0APC, APC2, AXIN1, AXIN2, CCND1, CDH1
17nucleusGO:00056347.3AMER1, APC, AXIN1, AXIN2, CCND1, CTNNB1

Biological processes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 41)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of catenin import into nucleusGO:003541410.9APC2, AXIN2
2regulation of centromeric sister chromatid cohesionGO:007060210.8AXIN2, CTNNB1
3cellular response to indole-3-methanolGO:007168110.8CDH1, CTNNB1
4maintenance of DNA repeat elementsGO:004357010.8AXIN2, MSH2
5cell fate specificationGO:000170810.8APC, APC2, CTNNB1
6determination of adult lifespanGO:000834010.7MSH2, TP53
7ovulationGO:003072810.7MYC, PTGS2
8regulation of microtubule-based processGO:003288610.7APC, GSK3B
9regulation of cell differentiationGO:004559510.7APC, APC2, CTNNB1
10mitotic G1 DNA damage checkpointGO:003157110.7CCND1, TP53
11dorsal/ventral axis specificationGO:000995010.7AXIN1, AXIN2, CTNNB1
12ER overload responseGO:000698310.7GSK3B, TP53
13somatic recombination of immunoglobulin gene segmentsGO:001644710.7MLH1, MSH2
14somatic recombination of immunoglobulin genes involved in immune responseGO:000220410.7MLH1, MSH2
15protein localization to microtubuleGO:003537210.7GSK3B, MAPRE1
16beta-catenin-TCF complex assemblyGO:190483710.6AXIN2, CTNNB1, MYC
17positive regulation of mitochondrial membrane potentialGO:001091810.6GSK3B, MYC
18cellular response to mechanical stimulusGO:007126010.6CTNNB1, GSK3B, PTGS2
19cellular response to organic cyclic compoundGO:007140710.6AXIN1, AXIN2, MYC
20cellular response to lithium ionGO:007128510.5CDH1, CTNNB1, GSK3B
21cellular response to UVGO:003464410.5MYC, PTGS2, TP53
22positive regulation of neuron apoptotic processGO:004352510.5CTNNB1, GSK3B, TP53
23cell migrationGO:001647710.4APC, APC2, GSK3B, SPATA13
24mismatch repairGO:000629810.4MLH1, MSH2, MUTYH, PMS1
25positive regulation of smooth muscle cell proliferationGO:004866110.4GSK3B, MYC, PTGS2
26positive regulation of protein catabolic processGO:004573210.4APC, APC2, AXIN1, GSK3B
27cell cycle arrestGO:000705010.3APC, MSH2, MYC, TP53
28response to X-rayGO:001016510.3CCND1, MSH2, TP53
29re-entry into mitotic cell cycleGO:000032010.3CCND1, GSK3B, MYC
30negative regulation of cell proliferationGO:000828510.3APC, AXIN2, CTNNB1, PTGS2, TP53
31beta-catenin destruction complex assemblyGO:190488510.3AMER1, APC, AXIN1, GSK3B
32Wnt signaling pathway involved in somitogenesisGO:009024410.1AXIN1, AXIN2
33beta-catenin destruction complex disassemblyGO:190488610.1AMER1, APC, AXIN1, CTNNB1, GSK3B
34canonical Wnt signaling pathwayGO:00600709.9APC, AXIN1, CCND1, CTNNB1, GSK3B, MYC
35response to estradiolGO:00323559.9CCND1, CTNNB1, GSK3B, MYC, PTGS2
36cellular response to DNA damage stimulusGO:00069749.9APC, CCND1, MLH1, MSH2, MYC, TP53
37cell proliferationGO:00082839.8APC2, AXIN2, CTNNB1, MAPRE1, MAPRE2, MYC
38proteasome-mediated ubiquitin-dependent protein catabolic processGO:00431619.8AMER1, APC, AXIN1, CTNNB1, GSK3B, TP53
39negative regulation of canonical Wnt signaling pathwayGO:00900909.6AMER1, APC, APC2, AXIN1, AXIN2, GSK3B
40response to drugGO:00424939.3APC, CCND1, CDH1, CTNNB1, GSK3B, MYC
41Wnt signaling pathwayGO:00160558.6AMER1, APC, APC2, AXIN1, AXIN2, CCND1

Molecular functions related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1MutSalpha complex bindingGO:003240711.0MLH1, MUTYH
2microtubule plus-end bindingGO:005101011.0APC, MAPRE1
3armadillo repeat domain bindingGO:007001610.9AXIN1, AXIN2
4MutLalpha complex bindingGO:003240510.9MSH2, MUTYH
5guanine/thymine mispair bindingGO:003213710.9MLH1, MSH2
6mismatched DNA bindingGO:003098310.8MSH2, PMS1
7I-SMAD bindingGO:007041110.8AXIN1, AXIN2, CTNNB1
8gamma-catenin bindingGO:004529510.8APC, APC2, CDH1
9double-stranded DNA bindingGO:000369010.4CTNNB1, MSH2, MYC, TP53
10RNA polymerase II transcription factor bindingGO:000108510.3CTNNB1, GSK3B, TP53
11single-stranded DNA bindingGO:00036979.8MLH1, MSH2, PMS1
12enzyme bindingGO:00198999.8AXIN1, AXIN2, CCND1, CTNNB1, MSH2, PTGS2
13beta-catenin bindingGO:00080139.7AMER1, APC, APC2, AXIN1, AXIN2, CDH1
14protein kinase bindingGO:00199019.3APC, AXIN1, AXIN2, CCND1, CTNNB1, GSK3B
15protein bindingGO:00055157.0AMER1, APC, APC2, AXIN1, AXIN2, CCND1

Sources for Adenomatous Polyposis Coli

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet